Inhibition of P450 17 as a new strategy for the treatment of prostate cancer

被引：29

作者：

Leroux, F ^{[1
]}

机构：

[1] Univ Strasbourg, ECPM, CNRS, UMR 7509,Lab Stereochim, F-67087 Strasbourg, France

来源：

CURRENT MEDICINAL CHEMISTRY | 2005年 / 12卷 / 14期

关键词：

androgen; 17 alpha-hydroxylase-C17,20-lyase; P450; 17; CYP; prostate cancer; steroidal inhibitors; non-steroidal inhibitors; abiraterone; liarozole;

D O I：

10.2174/0929867054367185

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The cytochrome P450 monooxygenase enzyme system is involved in the synthesis and/or degradation of a large number of endogenous compounds and in the biotransformation of drugs and other xenobiotics. 17 alpha-Hydroxylase-C17,20-lyase (P450 17, CYP 17) is the key enzyme of the androgen biosynthesis. As androgens have been implicated in the development and progression of prostate cancer, this enzyme has become a promising therapeutic target. This paper will review the possible approaches dealing with P450 17 inhibition as a chemotherapeutic strategy in the struggle against prostate cancer.

引用

页码：1623 / 1629

页数：7

共 54 条

[1]

Ahmed S, 1995, Drug Des Discov, V13, P27

[2]

Ahmed S, 1994, Drug Des Discov, V12, P77

[3] Time-dependent inactivation of steroid C-17(20)lyase by 17 beta-cyclopropyl ether-substituted steroids [J].

Angelastro, MR ;

Marquart, AL ;

Weintraub, PM ;

Gates, CA ;

Laughlin, ME ;

Blohm, TR ;

Peet, NP .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (01) :97-100

[4] 17-BETA-(CYCLOPROPYLAMINO)-ANDROST-5-EN-3-BETA-OL, A SELECTIVE MECHANISM-BASED INHIBITOR OF CYTOCHROME P45017-ALPHA (STEROID 17-ALPHA HYDROXYLASE-C17-20 LYASE) [J].

ANGELASTRO, MR ;

LAUGHLIN, ME ;

SCHATZMAN, GL ;

BEY, P ;

BLOHM, TR .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (03) :1571-1577

[5] INHIBITION OF TESTICULAR 17-ALPHA-HYDROXYLASE AND 17,20-LYASE BUT NOT 3-BETA-HYDROXYSTEROID DEHYDROGENASE-ISOMERASE OR 17-BETA-HYDROXYSTEROID OXIDOREDUCTASE BY KETOCONAZOLE AND OTHER IMIDAZOLE DRUGS [J].

AYUB, M ;

LEVELL, MJ .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1987, 28 (05) :521-531

[6] Inhibitors of cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20 lyase) [J].

Barrie, SE ;

Jarman, M .

[7] INHIBITION OF ESTROGEN BIOSYNTHESIS AND ITS CONSEQUENCES ON GONADOTROPIN-SECRETION IN THE MALE [J].

BHATNAGAR, AS ;

MULLER, P ;

SCHENKEL, L ;

TRUNET, PF ;

BEH, I ;

SCHIEWECK, K .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 41 (3-8) :437-443

[8] 3- and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C-17,C-20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer [J].

Chan, FCY ;

Potter, GA ;

Barrie, SE ;

Haynes, BP ;

Rowlands, MG ;

Houghton, J ;

Jarman, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) :3319-3323

[9] EXPERIMENTAL STUDIES WITH LIAROZOLE (R-75251) - AN ANTITUMORAL AGENT WHICH INHIBITS RETINOIC ACID BREAKDOWN [J].

DECOSTER, R ;

WOUTERS, W ;

VANGINCKEL, R ;

END, D ;

KREKELS, M ;

COENE, MC ;

BOWDEN, C .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 43 (1-3) :197-201

[10] P450-dependent enzymes as targets for prostate cancer therapy [J].

DeCoster, R ;

Wouters, W ;

Bruynseels, J .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 56 (1-6) :133-143

← 1 2 3 4 5 6 →